TNF Pharmaceuticals Share Holder Equity 2012-2024 | TNFA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

TNF Pharmaceuticals share holder equity from 2012 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

TNF Pharmaceuticals share holder equity from 2012 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$86.6B
Takeda Pharmaceutical (TAK)	$46.8B
Merck (MKGAF)	$24.9B
Summit Therapeutics (SMMT)	$23.1B
Astellas Pharma (ALPMY)	$21.7B
Sandoz Group AG (SDZNY)	$17.9B
United Therapeutics (UTHR)	$15.1B
Shionogi (SGIOY)	$13.2B
Neurocrine Biosciences (NBIX)	$12.3B
Catalent (CTLT)	$10.8B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.3B
Jazz Pharmaceuticals (JAZZ)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$4.3B
Corcept Therapeutics (CORT)	$4B
Dyne Therapeutics (DYN)	$3.4B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
PTC Therapeutics (PTCT)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Centessa Pharmaceuticals (CNTA)	$1.9B
Recursion Pharmaceuticals (RXRX)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.6B
Ardelyx (ARDX)	$1.5B
NewAmsterdam Pharma (NAMS)	$1.4B